Navigation Links
A 'Must Read' for Breast Cancer Patients
Date:12/18/2007

SAN JOSE, Calif., Dec. 18 /PRNewswire/ -- Patent 7,309,486 issued on 12/18/07 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses a better way of using Genentech's drug Herceptin(R) against breast cancer. The patent discloses that today's practice of concurrent administration of Herceptin(R) with conventional phase specific chemotherapy results in antagonistic action between the two classes of drugs. In later stage cancers, these protocols only increase median survival by several months.

Patent 7,309,486 discloses novel protocols that allow the two classes of chemotherapeutics to function synergistically. The protocols are designed to provide a way of holding the cancer in check indefinitely.

All proliferating cells progress through 4 distinct phases termed G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's Camptosar(R) or Eli Lilly's Gemzar(R), are capable of killing virtually all cells that are in the S-Phase, however, in the best case, only around one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "The patented protocols boost the number of cells in the S-Phase by exploiting the cancer's unique mutation profile to establish a "road block" to aggregate a large number of cancer cells at a point prior to the S-Phase, the road block is then removed to allow the wave of cancer cells to enter the S-Phase during the administration time of the S-Phase cytotoxic chemotherapy, and then the road block is reestablished to start aggregating surviving cancer cells for the next administration of S-Phase cytotoxic chemotherapy."

The abstract contained in the patent has been incorrectly truncated and a correct synopsis of the patent is available at http://www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Middle East Pharma Manufacturing/Biotech is Ready to Boom
2. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
3. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
7. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
10. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon ... from the U.S. Army Research Office and the ... range and sensitivity of the company,s Snapshot ... Accounting Mission and, more generally, defense-related DNA forensics. ... phenotyping capabilities (predicting appearance and ancestry from DNA ...
(Date:2/1/2016)... wallet ( www.wocketwallet.com ) announces the launch of a new video featuring ... Las Vegas , where Joey appeared at the Wocket booth ... , where Joey appeared at the Wocket booth to meet and ... at the Consumer Electronics Show (CES2016) in Las Vegas ... fans. --> --> The video ...
Breaking Biology News(10 mins):